{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:02:04Z","timestamp":1753891324910,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T00:00:00Z","timestamp":1710115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20fk0108532h0001"],"award-info":[{"award-number":["20fk0108532h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K09180"],"award-info":[{"award-number":["22K09180"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Coronavirus disease 2019 (COVID-19) features a hypercoagulable state, but therapeutic anticoagulation effectiveness varies with disease severity. We aimed to evaluate the dynamics of the coagulation profile and its association with COVID-19 severity, outcomes, and biomarker trajectories.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicenter, prospective, observational study included patients with COVID-19 requiring respiratory support. Rotational thromboelastometry findings were evaluated for coagulation and fibrinolysis status. Hypercoagulable status was defined as supranormal range of maximum clot elasticity in an external pathway. Longitudinal laboratory parameters were collected to characterize the coagulation phenotype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 166 patients, 90 (54%) were severely ill at inclusion (invasive mechanical ventilation, 84; extracorporeal membrane oxygenation, 6). Higher maximum elasticity (<jats:italic>P<\/jats:italic>=0.02) and lower maximum lysis in the external pathway (<jats:italic>P<\/jats:italic>=0.03) were observed in severely ill patients compared with the corresponding values in patients on non-invasive oxygen supplementation. Hypercoagulability components correlated with platelet and fibrinogen levels. Hypercoagulable phenotype was associated with favorable outcomes in severely ill patients, while normocoagulable phenotype was not (median time to recovery, 15 days vs. 27 days, <jats:italic>P<\/jats:italic>=0.002), but no significant association was observed in moderately ill patients. In patients with severe COVID-19, lower initial C3, minimum C3, CH50, and greater changes in CH50 were associated with the normocoagulable phenotype. Changes in complement components correlated with dynamics of coagulation markers, hematocrit, and alveolar injury markers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>While hypercoagulable states become more evident with increasing severity of respiratory disease in patients with COVID-19, normocoagulable phenotype is associated with triggered by alternative pathway activation and poor outcomes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1337070","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:50:52Z","timestamp":1710132652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between loss of hypercoagulable phenotype, clinical features and complement pathway consumption in COVID-19"],"prefix":"10.3389","volume":"15","author":[{"given":"Daisuke","family":"Kasugai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeo","family":"Kutsuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Goshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azusa","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naruhiro","family":"Jingushi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kamidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideshi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from Patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00762-9","article-title":"Understanding COVID-19-associated coagulopathy","volume":"22","author":"Conway","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.02.006","article-title":"Thromboprophylaxis in patients with COVID-19: A brief update to the CHEST guideline and expert panel report","volume":"162","author":"Moores","year":"2022","journal-title":"Chest"},{"key":"B4","doi-asserted-by":"publisher","first-page":"16025","DOI":"10.1038\/s41598-021-95512-7","article-title":"Mortality and risk factors associated with pulmonary embolism in coronavirus disease 2019 patients: a systematic review and meta-analysis","volume":"11","author":"G\u00f3mez","year":"2021","journal-title":"Sci Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051828","article-title":"Microthrombi as a major cause of cardiac injury in COVID-19: A pathologic study","volume":"143","author":"Pellegrini","year":"2021","journal-title":"Circulation"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/CCE.0000000000000427","article-title":"Is microthrombosis the main pathology in coronavirus disease 2019 severity?-A systematic review of the postmortem pathologic findings","volume":"3","author":"Fahmy","year":"2021","journal-title":"Crit Care Explor"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.09.001","article-title":"Anticoagulation in COVID-19 patients - An updated systematic review and meta-analysis","volume":"219","author":"Reis","year":"2022","journal-title":"Thromb Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-023-00599-6","article-title":"The effect of heparin full-dose anticoagulation on survival of hospitalized, non-critically ill COVID-19 patients: A meta-analysis of high quality studies","volume":"201","author":"Pilia","year":"2023","journal-title":"Lung"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1213\/ANE.0000000000000859","article-title":"Assessing the methodology for calculating platelet contribution to clot Strength (platelet component) in thromboelastometry and thrombelastography","volume":"121","author":"Solomon","year":"2015","journal-title":"Anesth Analg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000169225.31173.19","article-title":"Multi-centre investigation on reference ranges for ROTEM thromboelastometry","volume":"16","author":"Lang","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23599","article-title":"TEG and ROTEM: technology and clinical applications","volume":"89","author":"Whiting","year":"2014","journal-title":"Am J Hematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53175.x","article-title":"Care-needs certification in the long-term care insurance system of Japan","volume":"53","author":"Tsutsui","year":"2005","journal-title":"J Am Geriatr Soc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/1740774520939938","article-title":"Endpoints for randomized controlled clinical trials for COVID-19 treatments","volume":"17","author":"Dodd","year":"2020","journal-title":"Clin Trials"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.06.016","article-title":"Pulmonary thrombosis and thromboembolism in COVID-19","volume":"160","author":"Poor","year":"2021","journal-title":"Chest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2910","article-title":"Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19: A randomized clinical trial","volume":"327","author":"Bradbury","year":"2022","journal-title":"JAMA"},{"key":"B19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s13054-020-03401-8","article-title":"Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis","volume":"24","author":"Kruse","year":"2020","journal-title":"Crit Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1097\/TA.0000000000002963","article-title":"Hypercoagulable viscoelastic blood clot characteristics in critically ill coronavirus disease 2019 patients and associations with thrombotic complications","volume":"90","author":"Roh","year":"2021","journal-title":"J Trauma Acute Care Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1413","article-title":"SARS-CoV-2 triggers complement activation through interactions with heparan sulfate","volume":"11","author":"Lo","year":"2022","journal-title":"Clin Transl Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008248","article-title":"Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition","volume":"136","author":"Yu","year":"2020","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg0833","article-title":"SARS-CoV-2 drives JAK1\/2-dependent local complement hyperactivation","volume":"6","author":"Yan","year":"2021","journal-title":"Sci Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17098","article-title":"Genetic prediction of ICU hospitalization and mortality in COVID-19 patients using artificial neural networks","volume":"26","author":"Asteris","year":"2022","journal-title":"J Cell Mol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abo2341","article-title":"Complement C3 inhibition in severe COVID-19 using compstatin AMY-101","volume":"8","author":"Skendros","year":"2022","journal-title":"Sci Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abh2259","article-title":"Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection","volume":"6","author":"Ma","year":"2021","journal-title":"Sci Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03995-1","article-title":"Virus-induced senescence is a driver and therapeutic target in COVID-19","volume":"599","author":"Lee","year":"2021","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00785-2","article-title":"COVID-19 and cellular senescence","volume":"23","author":"Schmitt","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.cell.2021.12.040","article-title":"Complement activation induces excessive T cell cytotoxicity in severe COVID-19","volume":"185","author":"Georg","year":"2022","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00231.2021","article-title":"Erythrocytes identify complement activation in patients with COVID-19","volume":"321","author":"Lam","year":"2021","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.01.013","article-title":"Plasma proteomics of COVID-19-associated cardiovascular complications: implications for pathophysiology and therapeutics","volume":"7","author":"Roh","year":"2022","journal-title":"JACC Basic Transl Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1337070\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T04:51:00Z","timestamp":1710132660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1337070\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,11]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2024.1337070"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1337070","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2024,3,11]]},"article-number":"1337070"}}